Candidate Genes in Hypertension

Hayet Soualmia
High Institut of Medical Technologies of Tunis,
Biochemistry Laboratory LR99ES11, Rabta University Hospital, Tunis, Tunisia

1. Introduction

Essential hypertension (EH) is a polygenic and multifactorial disorder that results from genetic and/or environmental factors (Lifton et al., 2001). This disease has no identifiable origin, but results from a disturbance of systems regulating blood pressure (BP) such as several circulating and local neurohumoral and vasoactive factors. Genetic variations of these factors could play a role in the genesis of EH which represents a major risk factor for ischemic heart disease, stroke, peripheral vascular disease and progressive renal damage (Mesrati, 2007). EH rises with age, and it aggregates with other cardiovascular risk factors, such as dyslipidaemia, glucose intolerance, hyperinsulinaemia, abdominal obesity, and hyperuricaemia. Other environmental factors influence this disease like high dietary intake of sodium, alcohol, and stress. Family history, appears to play a major role because EH is more likely to develop in individuals when there is a strong family history. Several studies have identified a variety of candidate genes in EH as well as their interaction with one another and with the environment. Among these hypertension-predisposition genes investigated, genes involved in the renin-angiotensin-aldosterone system, catecholaminergic/adrenergic function, genes of signal transduction system as G protein β3-subunit, sodium channel system, α adducin and atrial natriuretic peptides. Several other biomarkers have been reported to increase the ability to predict EH such as hormone receptors like glucagon receptor and insulin like growth factor 1 (O'Shaughnessy, 2001, Timberlake et al., 2001) and other systems as endothelin, apolipoprotein and cytokine systems. In this chapter, we expose the genetic markers of EH and their expression related to lifestyle through several strategies such as investigation of specific candidate genes, genome-wide searches, use of intermediate phenotypes, comparative genomics and a combination of these methods (Timberlake et al., 2001)

2. Candidate genes in hypertension

A large number of candidate genes previously known and novel candidate genes that mediate susceptibility to hypertension are identified. The notion that hypertension is a polygenic disease, is reinforced by advanced biotechnological tools, and data are provided as to the actual number of genes involved, gene-gene interaction or gene-environment-interaction. The renin-angiotensin-aldosterone system is widely implicated and other gene systems are also emerging.
2.1 The renin-angiotensin-aldosterone system

The renin-angiotensin-aldosterone system (RAAS) is implicated in the control of BP and sodium balance. This system plays a key role in the regulation of kidney function. Genetic variations of components of the RAAS such as the renin (REN), angiotensinogen (AGT), angiotensin II-type 1 receptor (AGTR1), angiotensin-converting enzyme (ACE) (Allikmets et al., 1999) and aldosterone (CYP11B2) genes have been shown to be associated with susceptibility to EH.

2.1.1 Renin

Renin is the catalytic enzyme acting on angiotensinogen. It is encoded by the renin (REN) gene located at the 1q32 region. Several studies prove that the REN gene increases BP and susceptibility to hypertension. REN gene insertion/deletion (I/D) polymorphism is found to be associated with EH (Ying et al., 2010) and multiple REN SNPs are significantly associated with risk for hypertension. In the single SNP analysis, the strongest association with hypertension was seen with rs6693954, which is in high linkage disequilibrium with rs2368564 located at intron 9 (Sun et al., 2001). The REN-5312T allele has been reported to be associated with elevated diastolic BP (Vangjeli et al., 2010). Furthermore, the Bgl I variant in intron 1 and the 10501G/A SNP in exon 9 were associated with hypertension in US white and Gulf Arabs group from the United Arab Emirates (Frossard et al., 2001, Ahmad et al., 2005). In addition, an association of C-4021T and C-3212T with hypertension has been identified in African Americans (Zhu et al., 2003) and a SNP in intron 4 (54620025A/C) was shown to be associated with elevated BP and hypertension in Spanish women (Mansego et al., 2008). All these studies provide evidence that renin is an important candidate gene for EH.

2.1.2 Angiotensinogen

Angiotensinogen (AGT) gene located on chromosome 1q42-43, contains five exons spanning 13 kb (Gaillard et al., 1989). AGT is cleaved by renin to the decapeptide angiotensin (Ang) I precursor of Ang II. Significant evidence supporting the genetic susceptibility of the AGT locus for hypertension has been provided by many studies in various ethnic groups. A number of associated single nucleotide polymorphisms (SNPs) has been identified including M235T (rs669), T174M (rs4762), and G-217A (rs5049). Several studies have reported that the 235T and T174 allele increased the risk of EH (Jeunmaitre, 2008, Kunz et al., 1997, Fang et al., 2010, Sethi et al., 2003). Moreover, mutation in the promoter region that involves the presence of an adenine (A) instead of a guanine (G) 6 bp upstream from the transcription initiation site (G-6A) has been reported to have a positive correlation with hypertension (Wang et al., 2002). This mutation has been identified in a Taiwanese aboriginals, where the prevalence of the -6A and 235T variants of the AGT gene are high and are significantly associated with hypertension (Wang et al., 2002). Among all these AGT polymorphisms gene, the M268T variant is the most studied in several populations and represents a candidate gene for EH (Gopi-Chand et al., 2011).

2.1.3 Angiotensin-converting-enzyme

The angiotensin-converting-enzyme (ACE) is located on chromosome 17q23. In addition to increasing the production of Ang II, it is also responsible for the degradation of bradikinin, a
Candidate Genes in Hypertension

141

vasodilating and natriuretic substance. Several polymorphisms were present in the ACE gene but the prominent of these polymorphisms is the insertion or deletion (I/D) of 287 pb in intron 16 of this gene. Previous studies have reported that this polymorphism affected both serum ACE concentration and BP (Rigat et al., 1990), and DD genotype carriers have twice as high as ACE concentration compared to II genotype carriers, while subjects with ID genotype has intermediate or moderate ACE plasma concentration. In several studies, the D allele showed statistically significant relationship with hypertension in different populations. Thus, the ACE gene is a candidate gene for EH in humans.

2.1.4 Angiotensin II type 1 receptor

The human gene for angiotensin II type 1 receptor (AGTR1) located at chromosome 3q21-25, has a length of > 55 kb, is composed of five exons and four introns. A single nucleotide polymorphism (SNP) has been described in which there is either an adenine (A) or a cytosine (C) base (A/C) transversion in position 1166 in the 3’ untranslated region of the gene (Bonnardeaux et al., 1994). The +1166A/C polymorphism is the most studied and evaluated. Nine other SNPs influencing AGTR1 expression were described (Erdmann et al., 1999) and seven other SNPs reported in the 5’ flanking region of the gene, were not in linkage equilibrium with +1166A/C polymorphism (Poirier et al., 1998, Takahashi et al., 2000). Moreover, the SNP at nucleotide position +573 was investigated in hypertension and diabetes (Doria et al., 1997, Chaves et al., 2001) and several other new SNPs have been described, however, not all of them are associated with hypertension. In some studies, a linkage disequilibrium was shown between these new SNPs and the +1166 A/C polymorphism, in particular the -153 A/G polymorphism (Lajemi et al., 2001). In addition, the +1166 A/C variant in the AGTR1 gene was associated with the severe form of EH (Bonnardeaux et al., 1994; Kainulainen et al., 1999) and in Caucasian hypertensive subjects with a strong family history, the C allele was over-represented (Wang et al., 1997) and more frequent in women with pregnancy induced hypertension. Several other studies have reported significant interaction between the AGTR1 +1166A/C polymorphism and hypertension in different populations (Wang & Staessen, 2000, Henskens et al., 2003). So, the 1166 A/C polymorphism in the AGTR1 gene is a biomarker for EH.

2.1.5 Angiotensin II type 2 receptor

The angiotensin II type-2 receptor (AGTR2) gene is located on the X-chromosome. It consists of 3 exons and 2 introns, with the entire open reading frame of the AGTR2 located on exon 3 (Martin & Elton 1995). The AGTR2 is thought to oppose the growth promoting effect of the AGTR1 and was the mediator for vasodilatation, natriuresis and apoptosis of smooth muscle cells. A commonly occurring intronic polymorphism has been described at a lariat branch-point in intron 1 (Nishimura et al. 1999), although it has also been previously described by others (Erdmann et al., 2000) as (+1675). It is located 29 bp before exon 2, close to the region that is important for transcriptional activity (Warnecke et al. 1999). The AGTR2 A1675G polymorphism was shown to be involved in the development of EH in male (Zivkovic et al., 2007, Delles et al. 2000, Jin et al., 2003a, Alfakih et al., 2004), whereas the G4599A polymorphism located in exon 3 of the AGTR2 gene was associated with hypertension in women. Other SNPs in the
AGTR2 gene were identified by Zhang et al. (2003) suggesting a relationship between the 1334T/C polymorphism and the development of hypertension in a Chinese population.

2.1.6 Aldosterone synthase

The enzyme aldosterone synthase (CYP11B2) is the key enzyme in the final steps of aldosterone biosynthesis. It is encoded by the CYP11B2 gene located on chromosome 8q22 (Hilgers & Schmidt, 2005, Brand et al., 1998). Several polymorphisms have been identified in the CYP11B2 gene (White & Rainey, 2005). Among them, the promoter region C-344T polymorphism (rs id 1799998) is the best evaluated. This polymorphism either increases aldosterone to renin ratio in essential hypertensives or decreases aldosterone production, leading to sodium wasting and decreased excretion of potassium (Nicod et al., 2003, Matsubara et al., 2004). Furthermore, several studies have shown that the C-344T polymorphism is implicated in the risk of EH (Kumar et al., 2003, Gu et al., 2004) and other cardiovascular parameters. So the CYP11B2 gene is associated with the development of EH.

2.2 Sodium system

Several studies have examined the genetic influence on BP responses to dietary sodium and potassium intake in different populations. These studies have identified many candidate genes related to salt sensitivity of BP (Beeks et al., 2004). With the use of association or linkage studies, it appears that mutations increasing renal sodium reabsorption raise BP. The majority of these genes encode for renal ion channels and transporters or for components of hormonal or paracrine systems participating in the regulation of renal sodium reabsorption. All the genes involved in BP control are described in humans and in mice.

2.2.1 Epithelial Sodium channel

Epithelial sodium channel (Enac) is an amiloride sensitive epithelial sodium channel, composed of three subunits: α, β, and γ and encoded by different genes. SCNNIA gene coded for subunit α, located on human chromosome 12p13, and involved in aldosteronism and pseudohypoaldosteronism type I. SCNNIB and SCNNIG genes coded respectively for β, and γ subunits are related to monogenic form of salt sensitive hypertension (Kamida et al., 2004). The SCNNIA G2139 allele (Iwai, 2002, Wong, 1999) and Thr663Ala were reported to be associated with hypertension. A variety of mutations Gly589Ser, Thr594Met, Arg597His, Arg624Cys, Glu632Gly, Gly442Val and Val434Met has been shown in the SCNNIB gene and were implicated in the pathogenesis of systolic BP. In black individuals, the T594M mutation of the β subunit of this gene increases the risk of hypertension (Baker et al., 1998, Dong et al., 2002). In addition, a Japanese study (Matsubara et al., 2002) indicated a linkage between systolic BP and microsatellite markers on chromosome 16p12.3, a region close to the gene coding for the β and γ subunits of Enac gene (Wong et al.; 1999). Another study (Hyun-Seok et al., 2010) identified several SNPs in SCNNIB, SCNNIG genes and showed a link between hypertension and these polymorphisms. A recent study (Zhao et al., 2011) reported multiple common SNPs in SCNNIG associated with BP response to sodium intervention.
2.2.2 Thiazide sensitive Na+Cl- cotransporter

The sodium chloride cotransporter (NCC) is the thiazide sensitive Na-Cl cotransporter (TSC) located at the apical membrane of the distal convoluted tubule of the nephron (Plotkin et al., 1996), accounts for the absorption of 5% of the salt filtered at the glomerulus (Obermuller et al., 1995). The TSC gene, consisting of 26 exons that encode 1021 amino acid residues, is located on chromosome 16q13. Mutations in the human TSC gene is associated with a loss of TSC function, as seen in Gitelman’s syndrome, an autosomal recessive disease that affects BP regulation (Simon et al., 1996). Several TSC gene variants have been reported in different populations. TSC gene polymorphisms (C2736A, C1420T, G816C) were identified in Swedish population and only homozygous A2736 and T1420 alleles were significantly associated with EH in this population (Melander et al., 2000), whereas the G2736A was related to hypertension in Japanese women. Other SNPs of TSC gene rs7204044 and rs13306673 were studied in Mongolian and Han populations. TSC gene rs 7204044 is a genetic factor for EH in these two ethnicities, but rs13306673 is a genetic factor for EH only in Han population (Chang et al., 2011).

2.2.3 NEDD4L

NEDD4L is a ubiquitin ligase that controls the expression of the kidney epithelial sodium channels. The NEDD4L gene located on human chromosome 18q21, is an attractive candidate gene in pathogenesis for hypertensive disorders (Pankow et al., 2000). Several SNPs, including a common SNP (rs4149601) known to result in abnormal splicing, are identified in African Americans, American whites, and Greek whites with EH (Russo et al., 2005). In Swedish subjects, the rs4149601 polymorphism and an intronic NEDD4L marker (rs2288774) were associated with systolic and diastolic BP, as a consequence of altered NEDD4L interaction with EnaC (Fava et al., 2006). Moreover, SNP (rs513563) in NEDD4L was associated with hypertension in both African and Caucasian whites (Russo et al., 2005). In Chinese Hans, another rs3865418 variant of NEDD4L gene was implicated in the prevalence of EH in this population (Wen et al., 2008).

2.2.4 Na+ K+ /ATPase

The Na+K+/ATPase (NAK) is an integral membrane protein responsible for establishing and maintaining the electrochemical gradients of Na+ and K+ across the plasma membrane. The NKA is characterized by a complex molecular heterogeneity consisting of α, β and γ subunits. Four different α-polypeptides (α1, α2, α3, and α4) and three distinct β-isoforms (β1, β2, and β3) have been identified in mammalian. The α1 subunit is ubiquitous and predominates in the kidney, whereas the α2 subunit is most prevalent in the brain, heart, and muscle cells (Sweadner, 1989). The NAK catalytic subunit is encoded by multiple genes (Lalley et al., 1978) and separate genes encoding the α isoforms were identified in human (Shull & Lingrel, 1987). In mouse, the gene encoding the α1 subunit (ATP1A1) has been assigned to mouse chromosome 3. The α2 subunit gene (ATP1A2) is located on mouse chromosome 7 but the gene encoding the α3 subunit is located on mouse chromosome 1. The Na+K+/ATPase β3 subunit gene, which also exhibits a distinctive and complex tissue-specific pattern of expression (Mercer et al., 1986), maps to the same region of chromosome 1, but is not tightly linked to the α3 subunit gene. Genetic studies have reported that the 3’end of the gene for the α2 subunit (ATP1A2) and the β subunits (ATP1B1) variants were
associated with BP and hypertension (Shull et al., 1990, Kasantsev et al., 1992, Masharani & Frossard, 1988, Glenn et al., 2001) but the Bgl II ATP1A1 polymorphism gene in the first intron is associated with diabetic neuropathy (Vague et al., 1997). In addition, SNPs has been described, close to the ATP1A1 gene (D1S453, 160 kb) in Sardinian hypertensive and normotensive cohort (Glorioso et al., 2001). This study has identified an interaction of ATP1A1 and Na+K+2Cl-Cotransporter genes in Human EH.

2.3 Adducin

Adducin is a cytoskeleton protein that promotes the binding of spectrin with actin and may modulate a variety of other cell functions such as ion transport (Matsuoka et al., 2000). It is an heterodimeric protein consisting of an α-subunit and β-subunit or and α-subunit and γ-subunit, composed of three different subunits: adducin α, β, and γ which are encoded by three genes (ADD1, ADD2, ADD3) located on different chromosomes (Matsuoka et al., 2000). Adducin is one among the proteins that regulate Na+K+/ATPase activity. Abnormalities in adducin by genetic mutation have been shown to influence the surface expression and maximum velocity of Na+K+/ATPase and subsequently faster renal tubular Na+ reabsorption (Mische et al., 1987). Clinical and experimental studies have reported that the α adducin gene mutations could affect renal Na+ transport and explain a large proportion of BP variation (Bianchi et al., 1994, Barlassina et al., 1997), suggesting the involvement of mutated adducin variants in sodium-dependent hypertension. In animal models, single nucleotide polymorphisms (SNPs) in the ADD1 gene lead to increased tubular Na+ reabsorption and hypertension (Tripodi et al., 1996). In humans, a guanine to thymine SNP at nucleotide 614 in exon 10 of the ADD1 gene (rs4961) leads to a glycine (Gly) to tryptophan (Trp) change at amino acid position 460. This polymorphism has been associated with elevated untreated BP (Lanzani et al., 2005) and hypertension salt sensitivity (Barlassina et al., 2000, Turner et al., 2003).

2.3.1 ADD1

The gene encoding human ADD1 is mapped onto the chromosome location 4p16.3. Two missense mutations G460W and S586C in the human α adducin gene (ADD1) were shown to be associated with EH (Cusi et al., 1997). The common molecular variant of the ADD1 gene causing the substitution of tryptophan instead of glycine (Gly460Trp) at amino acid position 460 was found to be associated with increased risk of hypertension in different population (Cusi et al., 1997, Ju et al., 2003).

2.3.2 ADD2

C1797T ADD2 gene silent polymorphism in exon 15 was reported to be associated with hypertension in post menopausal women (Wang et al., 2002), in oral contraceptive users and in high salt intake populations. In Polish and Russian subjects (Tikhonoff et al., 2003), BP and the prevalence of hypertension were associated with the C1797T polymorphism in the β (ADD2), particularly in post menopausal women (Cwynar et al., 2005).

2.3.3 ADD 3

In ADD3 gene, the A to G substitution polymorphism located in intron 11 (IVS11 β386A>G –rs3731566) exists but neither previous publications nor genome browser databases
provided any suggestion about its functional role. Previous studies on populations and patients have demonstrated that the ADD1 Gly460Trp polymorphism, alone or in combination with variation in the ADD3 (IVS11 þ386A>G) or ACE (I/D) genes, influences the peripheral and central BP (Cwynar et al., 2005). Indeed, mean arterial pressure increased to the largest extent in patients carrying both the mutated ADD1Trp allele and the ADD3 GG genotype. Interaction between the ADD1 and ADD3 genes, which are located on different chromosomes, is in keeping with the heterodimeric structure of the adducin protein and strengthens the role of these genes compared with that of other loci mapping near to the adducin subunits (Kuznetsova et al., 2008).

2.4 Natriuretic peptides

The natriuretic peptide system (NP), with its diverse actions on renal and hemodynamic function and vasoactive hormone activity continues to attract attention as a potentially major regulator of body fluid volume and arterial pressure. The atrial natriuretic peptide (ANP), mainly produced by right atria in response to volume expansion, influences BP and body fluid homeostasis (Ogawa et al., 1995). This system consists of a family of three peptidic hormones A-type NP (ANP), B-type NP (BNP), and C-type NP (CNP) that interact with three receptors NP receptor A (NPRA), NP receptor B (NPRB) and NP clearance receptor (NPRC). The NPRC is encoded by the NPR3 gene and is a determinant of NP plasma concentration.

Genetic variants of the ANP system are involved in the etiology of hypertension (Rutlege et al., 1995, Kato et al., 2000), for this reason ANP is proposed as a candidate gene with salt-sensitive HT in some studies (Rutlege et al., 1995, Ciechnowicz et al., 1997). Several polymorphisms have been described in the human ANP gene: -C664G, G1837A, T2238C polymorphisms and a microsatellite marker of both NPRA and BNP genes were characterized (Rubattu et al., 2006). The T2238C ANP and the G1837A ANP intronic gene polymorphisms have been reported to be associated with left ventricular mass in human EH (Schmieder et al., 1996) and increased risk of ischemic stroke (Rubattu & Volpe, 2001). An I/D polymorphism at position 15129 of the 3’UTR of NPRA gene deletion variant is associated with hypertensive family history and higher systolic BP.

In the BNP gene, a variable number of tandem repeat (VNTR) polymorphism in the 5’-flanking region (-1241 nucleotides from the major transcriptional initiation site) was discovered. This VNTR polymorphism is a tandem repeat of the 4-nucleotide sequence TTTC appears to be a useful genetic marker of EH in females (Kosuge et al., 2007).

In CNP gene, four polymorphisms are identified : G733A, G1612C, G2347T and G2628A, two polymorphisms in the promoter region, one polymorphism in the coding region (exon 2) that accompanied an amino acid change from Gly to Val at amino acid position 61, and one polymorphism in the 3’-non coding region. Only the G2628A genotype in 3’-UTR was associated with BP and made greater contribution to hypertension (Ono et al., 2002). Overall these observations, suggested that atrial gene peptides could be considered candidate markers in EH.

2.5 Signal transduction pathways genes

The basic signal transduction steps are mediated through specific receptors binding, G protein coupled receptors and some growth factors. Specific receptors like adrenergic
receptors, glucagon receptor and growth factors as insulin-like growth factor 1 (IGF-I) genes are assumed to be important mediator in the pathophysiological response to BP increase. Mutation into the genes encoding signal transduction pathways have been associated with hypertension.

2.5.1 G Proteins

The main role of G proteins is to translate signals from the cell surface into a cell (Siffert, 2003) to mediate the intracellular effects of many hormones and peptides. A polymorphism C3T at nucleotide 825 in exon 10 of the β3 subunit of GTP binding protein (GNB3/C825T) has been identified (Bohm et al., 1997). This polymorphism is associated with enhanced intracellular signal transduction (Siffert et al., 1998) and has been reported to be associated with a variety of cardiovascular risk factors, including hypertension (Siffert et al., 1998, Schunkert et al., 1998, Benjafield et al., 1998), obesity (Siffert et al., 1999, Casiglia et al., 2008), diabetes (Bluthner et al., 1999) or dyslipidemia (Ishikawa et al., 2000, Hayakawa et al., 2007). A significantly higher frequency of the T allele has been identified in EH (Beige et al., 1999, Siffert, 1996). The mechanism whereby the 825T variant may lead to hypertension remains unknown, but it may involve an increase of Na-H exchanger activity (Siffert, 1996) which enhanced renal sodium reabsorption and induced the BP increase. Several studies have demonstrated that the 825T allele of GNB3 is associated with hypertension (Benjafield et al., 1998, Beige et al., 1999, Dong et al., 1999, Hengstenberg et al., 2001, Timberlake et al., 2001, Casiglia et al., 2008). Together, these studies highlight the importance of the GBN3/C825T variant gene in EH.

2.5.2 Glucagon receptor

The glucagon is involved in the regulation of electrolyte and water homeostasis. The effects of glucagon are mediated through its binding to a specific receptor (GCG-R), a 480-amino acid protein, which belongs to the superfamily of G protein–coupled transmembrane receptors (Laburthe et al., 1996). A Gly40Ser missense mutation in exon 2 of this receptor induced a lower affinity of the receptor for glucagon and a reduced cAMP response in transfected cells (Hansen et al., 1996). In humans, carriers of the mutation have a significantly lower increased plasma glucose concentration in response to glucagon infusion (Tonolo et al., 1997). A decrease in receptor activity in vivo might contribute to common EH by reducing the renal natriuretic effect of glucagon. Several studies have shown that the GCG-R plays a role in the predisposition to EH (Chambers & Morris, 1996, Tonolo et al., 1997). Other studies have reported significant association of the Gly40Ser polymorphism in hypertensive women with family history of hypertension in both parents (Chambers & Morris, 1996, Morris et al., 1997), whereas in French people, the Gly40Ser GCG-R variant was associated with hypertension only in men (Brand et al., 1999). Therefore, the glucagon receptor gene (GCG-R) could be a candidate gene for predisposition to human EH.

2.5.3 Insulin-like growth factor 1

The insulin-like growth factor 1 (IGF-I) is assumed to be an important mediator in the pathophysiological response to increased BP in the vessel wall, and low circulating IGF-I levels have been associated with cardiovascular disease development (Juul et al., 2002). The absence of the 192 bp allele in the promoter region of the IGF-I gene variant was associated
with low circulating IGF-I levels and linked to systolic BP. An increased risk of developing atherosclerosis was shown in hypertensive subjects with this IGF-I polymorphism. The genetic variation of the IGF-I receptor may affect the susceptibility to ischemic stroke (Cheng et al., 2008) and the diversity of left ventricular structure in hypertensives (Horio et al., 2010). The (IGF-I) is a mediator in limiting the damaging effects of high BP on the EH.

2.6 Noradrenergic system

The sympathetic nervous system acts through two main groups of adrenergic receptors, α and β with several subtypes α1 and α2 receptors and β receptors have the subtypes β1, β2 and β3, all linked to Gs proteins. The adrenergic system affects blood pressure by cardiac output and peripheral resistance regulation. Several studies have identified the implication of the β adrenergic receptors in the genesis of hypertension and many candidate gene studies have evaluated the association of one or more polymorphisms of adrenergic receptors in cardiovascular diseases, suggesting involvement of adrenergic pathways in EH.

2.6.1 β1-adrenergic receptor

The β1 adrenergic receptor (ADRB1), is a 7-transmembrane Gs protein coupled receptor. The ADRB1 is located on chromosome 10 (Hoehe et al., 1995) and is expressed in cardiac myocytes (Strader et al., 1994). Several polymorphisms of the ADRB1 exist, but two major single nucleotide Ser49Gly and Arg389Gly (Maqbool et al., 1999) are associated with BP. Arg389Gly variant is located in the intracellular cytoplasmic tail near the seventh transmembrane region of the receptor, which is a Gs-protein binding domain. The Arg389 polymorphism mediates a higher isoproterenol-stimulated adenylate cyclase activity than the Gly389 variant in vitro (Moore et al., 1999). The Ser49Gly polymorphism is located in the extracellular amino-terminal region of the receptor (Moore et al., 1999), but the potential functional consequence of this polymorphism is unknown. The genetic variants of the β1 adrenergic receptor could play an important role in the development of hypertension, because the β1 adrenergic receptor is essential in cardiac output regulation and the ADRB1 inhibitor reduces BP. Several studies have investigated the effects of these polymorphisms on resting haemodynamics and the incidence of hypertension, showing significantly higher diastolic BP and heart rates than siblings carrying either one or two copies of the 389G allele (Bengtsson et al., 2001).

2.6.2 β2-adrenergic receptor

The β2-adrenergic receptor (ADRB2) is responsible for vasodilatation in the vasculature via the cAMP pathway in smooth muscle cells or by release of nitric oxide (NO) from vascular endothelium (Eisenach et al., 2002). This receptor is implicated in the pathogenesis of hypertension. The ADRB2 gene located on chromosome 5q, is intronless, and codes for 413 amino acids. The most common SNPs in the ADRB2 gene include amino acid position 16, which contains either glycine or arginine (major/minor allele: Gly16/Arg), and amino acid position 27, which contains either glutamine or glutamic acid (Gln27/Glu). Some studies have shown that these two polymorphisms are associated with resistance to desensitization (Green et al., 1994, Green et al., 1995), but others have reported that the Gly16 variant ADRB2 gene is associated with EH in different populations (Lang et al., 1995, Svetkey et al., 1997, Kotanko et al., 1997, Timmermann et al., 1998, Lou Y et al., 2011). Moreover, another
variant, the A46G in the ADRB2 gene is significantly associated with EH risk only in male among the Northern Han Chinese population (Lou et al., 2011). Therefore, the β2 adrenergic receptor gene is considered a candidate gene for the development of EH.

2.6.3 β3-adrenergic receptor

The β3-adrenergic receptor (ADRB3) gene is located on chromosome 8p and codes for 396 amino acids. The ADRB3 gene contains a SNP that encodes either tryptophan or arginine (Trp64/Arg). This polymorphism is considered most relevant to lipolysis and thermogenesis. The ADRB3 genotype appears to have some influence in the development of obesity and appears to impact insulin resistance and the development of diabetes. So, The ADRB3 gene is not implicated in the risk of EH.

2.7 Endothelin system

Potent vasoconstrictor peptides, composed of three member family of peptides, namely endothelin-1 (ET-1), endothelin-2 (ET-2), endothelin-3 (ET-3) and their receptors, have a convincing role in EH. High circulating endothelin plasma levels have been reported in EH and genetic variants identified in the different component of endothelin system genes are involved in the etiology of hypertension.

2.7.1 Endothelin 1

Endothelin (ET)-1, produced by vascular endothelial cells, is a potent vasoconstrictor that acts as a modulator of vasomotor tone, cell proliferation, and vascular remodeling (Yanagisawa et al., 1988, Levin, 1995). The biological actions of ET-1 are mediated by two different receptors, ET-A receptor (ET-A) and ET-B receptor (ET-B). The interaction of ET-1 with ET-A in vascular smooth muscle cells is primarily responsible for ET-1-mediated vasoconstriction, whereas endothelial cell expressing ET-B promotes vasodilation (Haynes et al., 1995, Hirata et al., 1993). ET-1 is implicated in the pathogenesis of hypertension, heart failure, atherosclerosis, chronic kidney disease, and diabetes (MacGregor et al., 2000). High circulating endothelin plasma levels have been reported in EH. Human ET-1 gene is located on chromosome 6 and encodes a 21-amino acid peptide. Several SNPs in the endothelin system genes have been shown to have functional relevance and association with cardiovascular phenotypes and/or diseases (Taupenot et al., 2003). A G5665T polymorphism named Lys198Asn polymorphism of the preproendothelin-1 gene has been shown to be associated with higher BP in Caucasians and in Japanese populations with the T allele (Asai et al., 2001, Jin et al., 2003b). Therefore, the ET-1 is a candidate responsible for EH.

2.7.2 Endothelin 2

ET-2 is expressed in the right atria. A single A985G base change in the ‘3-UTR of the ET-2 gene was identified in hypertensives when BP was assessed as a quantitative trait. The difference in genotype and allele frequencies between the extremes of BP suggests that the ET-2 locus influences the severity rather than the initial development of hypertension (Sharma et al., 1999).
2.7.3 Endothelin-converting enzyme

Endothelin-converting enzyme (ECE) is a main component in endothelin (ET) biosynthesis, leading to the generation of ET-1, a potent vasoconstricting peptide, and contributing to BP control. Two different ECE genes, ECE-1 (Xu & Yanagisawa, 1994) and ECE-2 (Emoto & Yanagisawa, 1995), have been identified, but only ECE-1 expression is altered in human cardiovascular diseases. The gene is located at chromosome 1 (Albertin et al., 1996), has a length of 120 pb and is consisting of 20 exons (Schweizer et al., 1997, Valdenaire et al., 1999, Funke-Kaiser et al., 2000). Human ECE-1 is expressed in four different isoforms: ECE-1a, ECE-1b, ECE-1c and ECE-1d (Shimada et al., 1995, Valdenaire et al., 1999) generated from an additional promoters (Valdenaire et al., 1995, Valdenaire et al., 1999). The ECE-1b isoform expressed in endothelial and vascular smooth muscle cells (Valdenaire et al., 1999, Orzechowski et al., 1997), may contribute to vascular ET generation and BP regulation.

Several polymorphisms have been described in the human ECE-1b promoter gene, but only combinations of two common variants within the 5’-flanking region (T-839G, C-338A) were significantly associated with high BP values in non-treated hypertensive females (Funke-Kaiser et al., 2003). The -338A allele showed an increase in promoter activity compared with the wild-type promoter. Some studies conducted in African-American hypertensives have reported higher ECE-1 activity compared with white hypertensive patients (Grubbs et al., 2002), indicating that genetic variability in the ET system, e.g. ECE-1 gene, could be linked with severity of EH (Funke-Kaiser et al., 2003). So, the ECE-1 gene is a candidate gene in EH.

2.7.4 Endothelin receptors

ET-1 acts through two receptors ET-RA and ET-RB. Several single SNPs spanning the ET-RA gene were typed. The substitution of a thymine for a cytosine located in the untranslated part of exon 8 of the ET-RA gene was associated with pulse pressure and hypertension (Benjafield et al., 2003). In addition, an association was reported between genotype at the rs5335 (C+70G) SNP and night systolic BP and diastolic BP (Rahman et al., 2008). In this study the rs5335 (C+70G) polymorphism of the ET-RA receptor gene has small effects on the risk of hypertension. In another study (Ormezzano et al., 2005), the T allele of the ET-RA A/C+1222T polymorphism is associated with a reduction of baroreflex sensitivity in both healthy and hypertensive subjects. Likewise, a common polymorphism G1065A revealed that the AA+GA genotypes were significantly more frequent in salt-resistant than in salt-sensitive individuals, suggesting a protective role for the A allele (Caprioli et al., 2008).

2.7.5 Endothelial nitric oxide synthase

Nitric oxide synthase (eNOS) synthesizes nitric oxide (NO), a potent vasodilator produced by endothelial cells. The eNOS gene (NOS3) is located at the 7q35-q36 region, has a length of 21 kb and consisted of 26 exons. Variants of this gene have been investigated for association with hypertension and other cardiovascular disorders (Casas et al., 2006). Among them, three polymorphisms have been widely examined for clinical relevance (Casas et al., 2006, Cooke et al., 2007). A G894T substitution in exon 7 resulting in a replacement of Glu to Asp substitution at codon 298 (rs1799983), an insertion-deletion in intron 4 (4a/b) consisting of two alleles (the a-deletion which has four tandem 27-pb repeats and the b-insertion having five repeats), and a T786C substitution in the promotor region (rs2070744). Several
studies have shown significant association of the eNOS3 polymorphisms gene with hypertension (Uwabo et al., 1998, M. Shoji et al., 2000, Jachymova et al., 2001, Hyndman et al., 2002). In the Chinese population, a significant and independent association between the eNOS-G894T polymorphism and EH has been shown (Men et al., 2001). In addition, a meta-analysis of 33 studies have examined the eNOS G894T, 4a4b, T-786C, and G23T polymorphisms and their relationship to susceptibility for hypertension, and reported that: the allele 4b under a recessive model provided evidence of protection (Zintzaras et al., 2006). Thus, the eNOS gene is a risk factor for EH.

2.8 Apolipoproteins

Apolipoproteins are large complexes of molecules that transport lipids through the blood. They play a major role in lipid metabolism. Genetic variations identified in apolipoprotein genes have been shown to be involved in the risk of EH.

2.8.1 Apolipoprotein B

Apolipoprotein B (ApoB) is the main apolipoprotein of chylomicrons and low density lipoproteins (LDL), which occurs in the plasma in two main forms, ApoB48 and ApoB100. ApoB100 is synthesized in the liver and is present in very low density lipoproteins and their metabolic products. It is a principal ligand for low density lipoprotein (LDL) receptors (Boerwinkle et al., 1989) which mediate the uptake of LDL from the liver and peripheral cells. Like this, ApoB100 plays an important role in cholesterol homeostasis and a positive relationship has been established between coronary heart disease and LDL cholesterol with ApoB (Brunzell et al., 1984). The ApoB gene located at the 2p24 region (Knott et al., 1985), has a length of 42 kb, is composed of 29 exons (Blackhart et al., 1986). The 3' end of the ApoB gene exhibits a variable number of tandemly repeated (VNTR) short, A+T rich DNA sequences (Knott et al., 1986). Several studies have reported that ApoB 3′VNTR alleles is associated with EH (Philippe et al., 1999, Friedl et al., 1990).

2.8.2 Apolipoprotein C3

Genetic variation in the apolipoprotein C (ApoC3) gene, is associated with an increased risk of coronary heart diseases (CDH) (Sacks et al., 2000). ApoC3 is a protein of 79 amino acids, a constituent of triglyceride rich lipoprotein, including very low density lipoprotein (VLDL), chylomicron (CM), and high density lipoprotein (HDL) (Windler et al., 1985). It inhibits the lipoprotein lipase-induced hydrolysis of those particles (Ashavaid et al., 2002). ApoC3 exists in three different isoforms, according to the sialylation degree of the protein. Previous studies have shown that low ApoC3 levels may be associated with reduced CHD risk. Two polymorphisms located at positions −455 (T to C) and −482 (C to T) in the 5′ ApoC3 gene promoter region, have been shown to be associated with elevated levels of serum triglyceride and with a negative insulin response element (Dammerman et al., 1993). Another study has reported that the ApoC3 3206GG genotype was associated with a decrease in diastolic BP while the ApoC3 -482T allele was associated with a decrease in pulse pressure levels.

2.8.3 Apolipoprotein E

Apolipoprotein E (ApoE) gene situated on chromosome 19, appears in humans in three different forms named E2, E3 and E4 differing from each other by amino acid substitution in
two various positions (varying Cys112Arg and Arg158Cys) and coded by three alleles ε2, ε3 and ε4 at a single gene locus. ApoE polymorphism is one of the common genetic factors responsible for inter-individual variations in lipid and lipoprotein levels. ApoE4 has a higher and ApoE2 much lower affinity to the LDL receptor. The ε2 allele is associated with the lowest while the ε4 allele with the highest plasma cholesterol levels. Therefore, ApoE4 may be considered atherogenic (Curtiss & Boisvert, 2000), while ApoE2 seems to show a protective effect (Davignon et al., 1988). Some study has reported correlation between ApoE4 polymorphism and the incidence of CAD (Baroni et al., 2003). ApoE also seems to play a role in BP regulation. The ε4 allele influences the BP increasing effect of alcohol consumption. This gene environment interaction may have marked implications for the prevention and treatment of hypertension (Kauma et al., 1998).

2.8.4 Lipoprotein lipase

Lipoprotein lipase (LPL) is the main enzyme responsible for the hydrolysis of triglyceride (TG) present in circulating lipoproteins, and regulates high density lipoprotein concentrations. LPL gene located on chromosome 8p22 (Sparkes et al., 1987), has a length of 30 kb (Deeb & Peng, 1989), is composed of 10 exons. Mutations in locus intron 6 of LPL gene (Oka et al., 1989, Zuliani & Hobbs, 1990) lead to hypertriglyceridemia, dyslipidemia leading to various disorders as coronary artery disease, hypertension and obesity. The association between hypertension and the LPL locus (8p22) was reported by several studies (Chen et al., 2005, Yang et al., 2003). Significant evidence for linkage of systolic BP, but not diastolic BP has been associated with LPL locus located on the short arm of chromosome 8 (8p22) (Du-An et al., 1992). Another study has identified a S447X polymorphism in exon 9 of LPL gene that results from replacement of serine amino acid with a stop codon creating a restriction site. This study has reported that the more common SS genotype is associated with a lower LPL activity compared with the infrequent SX/XX genotype and carriers of (SS) genotype were at high risk of developing hypertension (Salah et al., 2009). Another study, has suggested that a high concentration of triglyceride and/or low concentration of HDL-cholesterol are associated with high systolic BP and pulse pressure in hypertensive patients with the X447 allele of the LPL gene (Liu et al., 2004). Therefore, the LPL gene is considered as a candidate gene that could contribute to the development of EH.

2.9 Cytokines

Interleukin-6 (IL-6) is a multifunctional cytokine involved in inflammation, potentially influencing BP. The human IL-6 gene is located on chromosome 7p21 (Bowcock et al., 1988). Genetic variations of the IL-6 gene have been reported, and the commonly studied polymorphism is the functional variant -174G>C (Fishman et al., 1998). Association of this polymorphism with coronary artery diseases has been reported in some studies (Rauramaa et al. 2000, Berg et al., 2009, Pola et al 2002). In addition, this polymorphism has been shown to be associated in vivo with high levels of IL-6 (Jenny et al., 2002, Brull et al., 2001). Previous studies (Ridker et al., 2000, Chae et al., 2001) have reported that increased IL-6 levels is correlated with high BP and may be an independent risk factor for hypertension. Moreover, in Japanese women, a weak association was reported between hypertension and other IL-6 gene promoter variants, the C/G substitution at -634, the G/A substitution at 4391 in a 3- non-coding portion of exon 5, and the A/T variation in the -447 position (Nakajima et al., 1999).
2.10 Neuropeptide Y

Neuropeptide Y (NPY) is a sympathetic cotransmitter with catecholamines (Takiyyuddin et al., 1994). It exhibits a vasoconstricting action and has multiple receptors, Y1-Y5. NPY interacts with the Y1 receptor (NPY1R) to control adrenergic activity and BP (Michalkiewicz et al., 2005). The gene encoding the NPY1R coupled with G proteins is located on chromosome 4q31.3-q32 (Eva et al., 2006). Genetic variation at the NPY1R locus has implications for heritable autonomic control of the circulation, and systemic hypertension (Wang et al., 2009). Several NPY1R variants have been identified in EH. Both the promoter A-585T and the 3'-UTR A+1050G variants had important effects upon both diastolic BP and systolic BP and interacted to determine diastolic BP. Homozygous for both the promoter variant major allele (A/A at A-585T) and the 3'-UTR variant minor allele (G/G at A+1050G) had dramatic BP elevation (Wang et al., 2009). Moreover, other studies have reported that hypertension is influenced by the NPY T1128C polymorphism in South Indian population (Bhaskar et al., 2010) and in a Swedish hypertensive population (Wallerstedt et al., 2004). Therefore, the NPY gene is a candidate marker in EH.

3. Gene-gene interactions in EH

Large numbers of gene variants have been described in EH, and the pathogenic role of gene-gene interaction has received increasing attention. Some study (Bell et al., 2006) has reported that the presence of epistatic interactions and locus heterogeneity in the underlying genetics of hypertension may explain the lack of replicated linkage (Williams, 2004). The developed linkage tests for multiple susceptibility loci applied to human data (Cordell, H.J., 1995, Cox, N.J., 1999) have contributed to advance of the gene-gene interactions studies, but these methods have examined only pre-selected regions. Thus, by two dimensional genome-scan approach, Bell et al., (2006) have identified significant evidence for loci on chromosomes 5, 9, 11, 15, 16 and 19, which influence hypertension when gene-gene interactions are taken into account (5q13.1 and 11q22.1, two-locus lod score 5 5.72; 5q13.1 and 19q12, two-locus lod score 5 5.35; 9q22.3 and 15q12, two-locus lod score 5 4.80; 16p12.3 and 16q23.1, two-locus lod score 5 4.50). Another study (Williams et al., 2000) has examined the effects of allele interactions at 4 candidate loci. Three of the loci are in the renin-angiotensin-system: angiotensinogen, ACE, and AGTR1, and they have been associated with hypertension. The fourth locus studied is a previously undescribed locus, named FJ. In total, seven polymorphic sites at these loci were analyzed for their association with hypertension in normotensive and hypertensive age-matched individuals. There were no significant differences between the 2 phenotypic classes with respect to either allele or genotype frequencies. In this report, when authors have tested for nonallelic associations (linkage disequilibrium), they found that of the 120 multilocus comparisons, 16 deviated significantly from random in the hypertensive class, but there were no significant deviations in the normotensive group. This study suggests that genetic interactions between multiple loci rather than variants of a single gene underlie the genetic basis of hypertension. The relation of many polymorphisms has been examined also in Chinese hypertensive patients (Dongfeng et al., 2006), in several candidate genes with the risk of hypertension: (1) renin-angiotensin-aldosterone system, including ACE, AGTR1, and CYP11B2, (2) sympathetic nervous system, including α-1 adrenergic receptor 1A (ADRA1), ADRB2, and tyrosine hydroxylase (TH); (3) lipoprotein metabolism, including LPL; (4) intracellular messengers, including GNB3 and NOS3; and (5) sodium and electrolyte balance, including G protein-
coupled receptor kinase 4 (GRK4) and protein kinase lysine-deficient 4 (WNK4). Both single-locus and multilocus analyses revealed that two genes from the sympathetic system (TH and ADRB2) and one gene affecting the sodium balance (GRK4) were independently associated with the significant risk of hypertension in the Chinese Han population. In addition to these 3 individual predictors, an interaction between CYP11B2 and AGTR1, both from RAAS, was also found to be involved in the relationship with hypertension. These findings support the recognized understanding that complex genetic interactions account for hypertension risk. Additional studies have genotyped hypertensives at the AGT M235T, ACE I/D, CYP11B2 C-344T, REN, AGTR1 and/or ADD loci, have reported that combinations of polymorphisms at several of these loci steadily increase the odds ratio of predicting hypertension (Agachan B et al., 2003, Vasku A et al., 1998, Tsai CT et al., 2003). Another study (Tomaszewski et al., 2006) revealed epistatic interaction between ADRB2 and NPY in regulation of LDL levels in hypertensive subjects. The effect of NPY locus appears to be altered by ADRB2. Specifically, Leu7Leu genotype within NPY SNP was associated with increased concentrations of LDL only in the presence of Arg16Gln27. Taken together all these studies provide evidence that several functional polymorphisms within candidate genes act individually or together in the etiology of EH.

4. Conclusion

The actual number of candidate genes detected in EH studies reinforced the highly polygenic nature of this disease. Knowing the genes responsible for this condition is an important prerequisite to prevent the expression of these disease markers related to lifestyle, especially for predisposed subjects at risk. From a large series of studies conducted in humans and animals, the renin-angiotensin-aldosterone system constituted risk genes and other systems like sodium system genes, signal transduction system genes, endothelial system genes, and neurohormonal and adrenergic genes were involved in genetic predisposition of EH. In addition, several lessons could be learned from these genetic studies and applied to other additional candidate genes that would be necessary to identify in EH. Actual strategies used for genetic studies showed some limitations. As well the candidate gene strategy (which assumes that a given gene, or a set of genes involved in a specific function, might contribute in BP variation) as linkage and/or association studies suffered from limited sample sizes and a low prior probability of the selected candidate genes being associated with hypertension. Moreover, the sequence variants influencing the phenotype of EH have remained elusive, but with better mapping techniques, better phenotyping methods and systems biology approach, and potential gene-gene interactive model, we should begin to discover those variants that could lead to its enhanced prevention, detection, and treatment of EH.

5. References


Ashavaid, TF.; Shalia, KK.; Kondkar, AA.; Todur, SP.; Nair, KG. & Nair, SR. (2002). Gene polymorphism and coronary risk factors in Indian population. *Clin Chem Lab Med* 40:975-985


Bianchi, G.; Tripodi, G.; Casari, G.; Salardi, S.; Barber, BR.; Garcia, R.; Leoni, P.; Torielli, L.; Cusi, D.; Ferrandi, M. (1994). Two point mutations within the adducin genes are involved in blood pressure variation. *Proc Natl Acad Sci USA* 91:3999-4003


Brull, DJ.; Montgomery, HE.; Sanders, J.; Dhamrait, S.; Luong, L.; Rumley, A.; Lowe, GD. & Humphries, SE. (2001). Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. *Arterioscler Thromb Vasc Biol* 21:1458-63

Chae, CU.; Lee, RT.; Rifai, N & Ridker, PM. (2001). Blood pressure and inflammation in apparently healthy men. Hypertension 38:399-403
Cox, NJ.; Frigge, M.; Nicolae, DL.; Concannon, P.; Hanis, CL.; Bell, GI. & Kong, A. (1999) Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans. Nat Genet :21, 213 -215
interaction between α and γ-adducin influences peripheral and central pulse pressure in White Europeans. J Hypertens 23:961-969

Dammerman, M.; Sandkuijl, LA.; Halaas, JL.; Chung, W. & Breslow, JL. (1993). An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 90:4562-4566


Dong, YB.; Plange-Rhule, J.; Owusu, I.; Micah, F.; Eastwood, JB.; Carter, ND.; Saggar-Malik, AK.; Cappuccio, FP. & Jeffery, S. (2002). T594M mutation of the beta-subunit of the epithelial sodium channel in Ghanaian populations from Kumasi and London and a possible association with hypertension. Genet Test 6:63-5


Fang, YJ.; Deng, HB.; Thomas, GN.; Tzang, CH.; Li, CX.; Xu, ZL.; Yang, M. & Tomlinson, B. (2010). Linkage of angiotensinogen gene polymorphisms with hypertension in a sibling study of Hong Kong Chinese. *J Hypertens* 28: 1203-1209


Henskens, LH.; Spiering, W.; Stoffers, HE.; Soomers, FL.; Vlitchinck, RF.; de Leeuw, PW. & Kroon, AA. (2003). Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population: first results of the Hippocrates study. *J Hypertens* 21:81-6


synthase gene with essential hypertension resistant to conventional therapy. 
*Biochem Biophys Res Commun* 284:426-430

Jenny, NS.; Tracy, RP.; Ogg, MS.; Luongle, A.; Kuller, LH.; Arnold, AM.; Sharrett, AR. & Humphries, SE. (2002). In the elderly, interleukin-6 plasma levels and the _174G>C_ polymorphism are associated with the development of cardiovascular disease. *Arterioscler Thromb Vasc Biol* 22:2066-71


Knott, TJ.; Wallis, SC.; Powell, LM.; Pease, RJ.; Lusis, AJ.; Blackhart, B.; McCarthy, BJ.; Wilson, B. & Scott, J. (1986). A hypervariable region 3′ to the human apolipoprotein B gene. *Nucleic acids research* 14:7501-7503


Moore, JD.; Mason, DA.; Green, SA.; Hsu, J. & Liggett, SB. (1999). Racial differences in the frequencies of cardiac β 1-adrenergic receptor polymorphisms: analysis of c145A3G and c1165G3C. *Hum Mutat* 14:271


Pankow, JS.; Rose, KM.; Oberman, A.; Hunt, SC.; Atwood, LD.; Djousse, L.; Province, MA. & Rao, DC.; (2000). Possible locus on chromosome 18q influencing postural systolic blood pressure changes. *Hypertension* 36:471-476


Russo, CJ.; Melista, E.; Cui, J.; De Stefano, AL.; Bakris, GL.; Manolis, AJ.; Gavras, H. & Baldwin, CT. (2005). Association of NEDD4L Ubiquitin Ligase with Essential Hypertension. *Hypertension* 46:488-491


Svetkey, LP.; Chen, YT.; McKeown, SP.; Preis, L. & Wilson, AF. (1997). Preliminary evidence of linkage of salt sensitivity in black Americans at the beta-2 adrenergic receptor locus. *Hypertension* 29:918-922


Williams, SM.; Addy, JH.; Phillips, JAIIL.; Dai,DM.; Kpodonu J, Aful, J; Jackson, H.; Joseph, K.; Eason, F.; Murray, MM.; Epperson, P.; Aduonum, A.; Wong, LJ.; Jose, PA.; &
Genetics and Pathophysiology of Essential Hypertension


Wong, ZY.; Stebbing, M.; Ellis, JA.; Lamantia, A. & Harrap, SB. (1999). Genetic linkage of beta and gamma subunits of epithelial sodium channel to systolic blood pressure. *Lancet* 353:1222-1225


Ying, CQ.; Wang, YH.; Wu, ZL.; Fang, MW.; Wang, J.; Li, YS.; Zhang, YH. & Qiu, CC. (2010). Association of the renin gene polymorphism, three angiotensinogen polymorphism and the haplotypes with essential hypertension in the Mongolian population. *Clin Exp Hypertens* 32:293-300


This book, authored by renowned researchers in the field of Hypertension Research, details the state of the art knowledge in genetics, genomics and pathophysiology of Essential hypertension, specifically the genetic determinants of hypertension and role of gene variants in response to anti-hypertensive therapy. Two chapters describe mitochondrial mutations in Essential hypertension and in hypertension associated Left ventricular hypertrophy, one chapter reviews in detail the global gene expression in hypertension, and an up to date treatise on pathophysiology of resistant hypertension is detailed in another chapter. Other topics included in the book are end organ damage, baroreceptor sensitivity and role of music therapy in essential hypertension.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: